Letter: NSBB for fatty liver disease-Still a long way to go. Authors' reply

Aliment Pharmacol Ther. 2023 Oct;58(8):848-849. doi: 10.1111/apt.17702.

Authors

Mathias Jachs^{1

2}, Rafael Paternostro^{1

2}, Thomas Reiberger^{1

2

3}, Mattias Mandorfer^{1

2}

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
² Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
³ Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.

PMID: 37768295
DOI: 10.1111/apt.17702

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease*